<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00601640</url>
  </required_header>
  <id_info>
    <org_study_id>07-0032-04</org_study_id>
    <secondary_id>P30CA023074</secondary_id>
    <secondary_id>P01CA027502</secondary_id>
    <secondary_id>UARIZ-BIO-06182</secondary_id>
    <secondary_id>07-0032-04</secondary_id>
    <nct_id>NCT00601640</nct_id>
  </id_info>
  <brief_title>Eflornithine and/or Diclofenac in Treating Patients With Sun-Damaged Skin</brief_title>
  <official_title>Phase IIB Study to Evaluate the Safety and Efficacy of Topical Difluoromethylornithine and Topical Diclofenac in the Treatment of Sun-Damaged Skin on the Forearm</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arizona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Arizona</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming. The use
      of eflornithine and diclofenac may stop cancer from growing in patients with sun-damaged
      skin.

      PURPOSE: This randomized phase II trial is studying the side effects and how well
      eflornithine works compared with diclofenac, given alone or together, in treating patients
      with sun-damaged skin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To determine if combination therapy with topical eflornithine hydrochloride ointment and
           topical diclofenac sodium gel over 3-months increases the efficacy versus either agent
           used alone in the treatment of moderately sun-damaged skin.

      Secondary

        -  To evaluate the safety of sequential administration of topical eflornithine
           hydrochloride ointment and topical diclofenac sodium gel.

        -  To determine the correlation of karyometric changes with histopathologic,
           immunohistochemical, clinical, and genetic polymorphism data.

        -  To obtain materials for microarray analysis.

      OUTLINE: Patients are randomized to 1 of 3 treatment arms.

        -  Eflornithine hydrochloride : Patients apply topical eflornithine hydrochloride ointment
           to their left forearm twice daily on days 1-90.

        -  Diclofenac sodium : Patients apply topical diclofenac sodium gel to their left forearm
           once daily on days 1-90.

        -  Eflornithine hydrochloride/Diclofenac sodium : Patients apply topical eflornithine
           hydrochloride ointment as in arm I twice daily and topical diclofenac sodium gel as in
           arm II once daily on days 1-90.

      Prior to treatment, three 4-mm punch biopsies are taken from the skin of the left lateral
      forearm for assessment of histopathology, the cyclooxygenase-2 enzyme and p53 expression,
      apoptosis, and nuclear chromatin karyometry. Tissue is also obtained for future use in
      microarray analysis. Blood is drawn for assessment of ornithine decarboxylase polymorphisms
      and for banking for subsequent studies. Biopsies are repeated 2-3 weeks after completion of
      treatment.

      Digital photographs are taken at baseline and 1-2 weeks after completion of study therapy to
      document improvement of sun damage, appearance of new skin lesions, and toxicity.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Putrescine Over 3 Months</measure>
    <time_frame>3 months</time_frame>
    <description>Putrescine is measured in nmole/g skin per biopsy. Baseline and End of Study biopsies were measured and the change was produced by subtracting baseline levels from End of Study levels. There was one baseline biopsy and one End of Study biopsy per participant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of Combination Therapy With Topical Eflornithine Hydrochloride Ointment and Topical Diclofenac Sodium Gel Over 3-months</measure>
    <time_frame>3 months</time_frame>
    <description>Adverse events were compared across three treatment groups by severity determined by the clinician. All adverse events were resolved by the end of follow up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Histologic Score Diagnosis and Treatment Group</measure>
    <time_frame>3 months</time_frame>
    <description>Change scores were computed by subtracting baseline histologic score from End of Study histologic score. Slides were formalin fixed. Histologic Score has been developed by this research group over the course of Grant (reference below). A standardized form captures data on the following criteria: basal or suprabasilar pleomorphism (atypia); inflammation; hyperkeratosis; parakeratosis. The atypia and inflammation were rated as: none (0), mild to moderate(1), and severe (2). The remaining criteria were rated as present (1) or absent (0). Histologic Scores were computed by adding together the codes for the histologic criteria. Higher scores reflected higher level of epidermal /dermal damage.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">184</enrollment>
  <condition>Other Benign Neoplasm of Skin, Unspecified</condition>
  <arm_group>
    <arm_group_label>Eflornithine HCL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients apply Eflornithine HCL ointment to their left forearm twice daily on days 1-90.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diclofenac Na</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients apply topical Diclofenac Na gel to their left forearm once daily on days 1-90.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Eflornithine HCL and Diclofenac Na</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eflornithine HCl ointment and Diclofenac Na gel applied twice and once daily, respectively on days 1-90.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diclofenac Na gel</intervention_name>
    <description>Given topically twice daily on days 1-90</description>
    <arm_group_label>Diclofenac Na</arm_group_label>
    <arm_group_label>Eflornithine HCL and Diclofenac Na</arm_group_label>
    <other_name>Solaraze</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eflornithine HCL ointment</intervention_name>
    <description>Given topically twice daily on days 1-90</description>
    <arm_group_label>Eflornithine HCL</arm_group_label>
    <arm_group_label>Eflornithine HCL and Diclofenac Na</arm_group_label>
    <other_name>Vaniqa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Visible sun-induced damage to the skin as assessed by the study dermatologists

          -  No inflammation of the skin on the lateral forearms

          -  No more than 10 actinic keratoses on the left forearm, and no actinic keratoses in the
             treatment area

          -  Resident of Pima or an adjoining Southern Arizona county

          -  History of treated basal cell carcinoma and/or squamous cell carcinoma of the skin at
             any site other than the left forearm allowed if excision or topical treatment was
             completed more than 30 days ago (60 days for radiotherapy)

          -  History of treated basal cell carcinoma and/or squamous cell carcinoma of the skin on
             the left forearm allowed 6 months after treatment is completed

          -  Must agree to avoid sun exposure to the left forearm as much as possible

          -  Not pregnant or nursing

          -  Not moderately to highly immunosuppressed by virtue of medication or disease, except
             for mildly suppressive disorders (e.g., diabetes mellitus or on mildly
             immunosuppressive therapy such as inhaled steroids for asthma)

          -  No serious concurrent illness that could interfere with study participation

          -  No active peptic ulcer disease, bleeding disorder, renal failure (creatinine &gt; 2.0
             mg/dL), or porphyria

          -  No known hypersensitivity to diclofenac sodium, eflornithine, acetylsalicylic acid, or
             NSAIDS

          -  No evidence of serious underlying medical conditions as demonstrated by abnormal
             values on baseline laboratory assessment

          -  More than 6 months since prior chemotherapy and in complete remission

          -  More than 60 days since prior and no concurrent oral diclofenac sodium (Cataflam®,
             Voltaren®, Voltaren-XR®) or combination of diclofenac and misoprostol (Arthrotec®)

          -  More than 60 days since prior and no concurrent IV eflornithine hydrochloride

          -  More than 30 days since prior and no concurrent topical retinoids, steroids, imiquimod
             (Aldara®), aminolevulinic acid HCl (Levulan®), eflornithine (Vaniqa®), diclofenac
             sodium gel (Solaraze®), or fluorouracil at any site

          -  More than 30 days since prior and no concurrent topical medication, other than
             emollients or sunscreens, on the left forearm

          -  Not undergoing concurrent bone marrow or solid organ transplant

          -  No concurrent immunosuppressive therapy (e.g., systemic chemotherapy or rheumatologic
             agents such as infliximab [Remicade®])

          -  No concurrent sunscreen use to the left forearm

          -  No concurrent active therapy for any invasive cancer

          -  No concurrent NSAIDs for more than 14 days per month for arthritic and other pain
             conditions

          -  Concurrent prednisone or other steroids with doses up to 20 mg/day (or the equivalent
             dose) allowed

          -  At least 30 days since prior and no concurrent enrollment on other investigational
             drug or device trial

        Exclusion Criteria:

          -  Individuals receiving concurrent topical therapy with retinoids, steroids,
             5-fluorouracil, Levulan, Vaniqa (eflornithine), Solaraze, or Imiquimod (Aldara®)
             within 30 days prior to study enrollment will be excluded. Subjects may be
             reconsidered for eligibility 30 days after the last topical treatment.

          -  Individuals who have had treatment for basal cell carcinoma or squamous cell carcinoma
             of the skin of the left forearm within six months prior to evaluation for the study
             will not be eligible. If interested, these subjects will be encouraged to return for
             re-evaluation once the six-month period is over.

          -  Individuals who are moderately to highly immunosuppressed by virtue of medication or
             disease will not be allowed to participate. This category includes individuals
             undergoing bone marrow or solid organ transplant, or receiving immunosuppressive
             therapy such as systemic chemotherapy or rheumatologic agents such as infliximab
             (Remicade®). However, individuals with mildly suppressive disorders such as diabetes
             mellitus or on mildly immunosuppressive therapy such as inhaled steroids for asthma
             will be eligible for participation. Doses up to 20 mg of prednisone per day or the
             equivalent dose of other steroids will be allowed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joanne M. Jeter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arizona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Virginia G. Piper Cancer Center at Scottsdale Healthcare - Shea</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center - Tucson</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Cancer Center at University of Arizona Health Sciences Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724-5024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bozzo P, Saboda K, Einspahr JG, Ranger-Moore J, Farmer ER, Cockerell CJ, Elder DE, Bangert JL, Hart N, Kramer CB, Alberts DS. Reliability and validity of a histologic score as a marker for skin cancer chemoprevention studies. Anal Quant Cytol Histol. 2003 Oct;25(5):285-92.</citation>
    <PMID>14603727</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 22, 2008</study_first_submitted>
  <study_first_submitted_qc>January 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2008</study_first_posted>
  <results_first_submitted>April 15, 2011</results_first_submitted>
  <results_first_submitted_qc>February 2, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 23, 2017</results_first_posted>
  <last_update_submitted>February 2, 2017</last_update_submitted>
  <last_update_submitted_qc>February 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>skin cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Skin Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diclofenac</mesh_term>
    <mesh_term>Eflornithine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>184 participants were accrued. 18 were accrued when an interim analyses resulted in a change in formulation and dosing. The primary analyses is based on 166 accrued after this change.</recruitment_details>
      <pre_assignment_details>166 participants were accrued after the change in formulation. 10 participants were not randomized for various reasons. 156 participants were randomized to one of the 3 treatment groups.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Eflornithine Hydrochloride</title>
          <description>Patients apply topical eflornithine hydrochloride ointment to their left forearm twice daily on days 1-90.</description>
        </group>
        <group group_id="P2">
          <title>Diclofenac Sodium</title>
          <description>Patients apply topical diclofenac sodium gel to their left forearm once daily on days 1-90.</description>
        </group>
        <group group_id="P3">
          <title>Eflornithine Hydrochloride/Diclofenac Sodium</title>
          <description>Patients apply topical Eflornithine hydrochloride ointment as in arm I twice daily and topical Diclofenac sodium gel as in arm II once daily on days 1-90.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="52"/>
                <participants group_id="P3" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="47"/>
                <participants group_id="P3" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>intercurrent illness</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>change in eligibility status</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm I</title>
          <description>Patients apply topical eflornithine hydrochloride ointment to their left forearm twice daily on days 1-90.</description>
        </group>
        <group group_id="B2">
          <title>Arm II</title>
          <description>Patients apply topical diclofenac sodium gel to their left forearm once daily on days 1-90.</description>
        </group>
        <group group_id="B3">
          <title>Arm III</title>
          <description>Patients apply topical eflornithine hydrochloride ointment as in arm I twice daily and topical diclofenac sodium gel as in arm II once daily on days 1-90.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="52"/>
            <count group_id="B2" value="52"/>
            <count group_id="B3" value="52"/>
            <count group_id="B4" value="156"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="102"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.3" spread="9.5"/>
                    <measurement group_id="B2" value="60.4" spread="11.0"/>
                    <measurement group_id="B3" value="61.4" spread="10.4"/>
                    <measurement group_id="B4" value="60.4" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="112"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="52"/>
                    <measurement group_id="B4" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes in Putrescine Over 3 Months</title>
        <description>Putrescine is measured in nmole/g skin per biopsy. Baseline and End of Study biopsies were measured and the change was produced by subtracting baseline levels from End of Study levels. There was one baseline biopsy and one End of Study biopsy per participant.</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Eflornithine Hydrochloride</title>
            <description>Patients apply topical eflornithine hydrochloride ointment to their left forearm twice daily on days 1-90.</description>
          </group>
          <group group_id="O2">
            <title>Diclofenac Sodium</title>
            <description>Patients apply topical diclofenac sodium gel to their left forearm once daily on days 1-90.</description>
          </group>
          <group group_id="O3">
            <title>Eflornithine Hydrochloride/Diclofenac Sodium</title>
            <description>Patients apply topical Eflornithine hydrochloride ointment as in arm I twice daily and topical Diclofenac sodium gel as in arm II once daily on days 1-90.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Putrescine Over 3 Months</title>
          <description>Putrescine is measured in nmole/g skin per biopsy. Baseline and End of Study biopsies were measured and the change was produced by subtracting baseline levels from End of Study levels. There was one baseline biopsy and one End of Study biopsy per participant.</description>
          <units>nmol/g skin</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="1.12"/>
                    <measurement group_id="O2" value="1.45" spread="1.23"/>
                    <measurement group_id="O3" value="0.2" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety of Combination Therapy With Topical Eflornithine Hydrochloride Ointment and Topical Diclofenac Sodium Gel Over 3-months</title>
        <description>Adverse events were compared across three treatment groups by severity determined by the clinician. All adverse events were resolved by the end of follow up.</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Eflornithine Hydrochloride</title>
            <description>Patients apply topical eflornithine hydrochloride ointment to their left forearm twice daily on days 1-90</description>
          </group>
          <group group_id="O2">
            <title>Diclofenac Sodium</title>
            <description>Patients apply topical diclofenac sodium gel to their left forearm once daily on days 1-90.</description>
          </group>
          <group group_id="O3">
            <title>Eflornithine Hydrochloride/Diclofenac Sodium</title>
            <description>Patients apply topical eflornithine hydrochloride ointment as in arm I twice daily and topical diclofenac sodium gel as in arm II once daily on days 1-90</description>
          </group>
        </group_list>
        <measure>
          <title>Safety of Combination Therapy With Topical Eflornithine Hydrochloride Ointment and Topical Diclofenac Sodium Gel Over 3-months</title>
          <description>Adverse events were compared across three treatment groups by severity determined by the clinician. All adverse events were resolved by the end of follow up.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Burning and Stinging None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Burning and stinging Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>burning and stinging Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Burning and Stinging Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pruritis None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pruritis Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pruritis Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pruritis Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash, Redness. Erythema-None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash, Redness. Erythema-Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash, Redness. Erythema-Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash, Redness. Erythema-Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.022</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Histologic Score Diagnosis and Treatment Group</title>
        <description>Change scores were computed by subtracting baseline histologic score from End of Study histologic score. Slides were formalin fixed. Histologic Score has been developed by this research group over the course of Grant (reference below). A standardized form captures data on the following criteria: basal or suprabasilar pleomorphism (atypia); inflammation; hyperkeratosis; parakeratosis. The atypia and inflammation were rated as: none (0), mild to moderate(1), and severe (2). The remaining criteria were rated as present (1) or absent (0). Histologic Scores were computed by adding together the codes for the histologic criteria. Higher scores reflected higher level of epidermal /dermal damage.</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Eflornithine Hydrochloride</title>
            <description>Patients apply topical eflornithine hydrochloride ointment to their left forearm twice daily on days 1-90.</description>
          </group>
          <group group_id="O2">
            <title>Diclofenac Sodium</title>
            <description>Patients apply topical diclofenac sodium gel to their left forearm once daily on days 1-90.</description>
          </group>
          <group group_id="O3">
            <title>Eflornithine Hydrochloride/Diclofenac Sodium</title>
            <description>Patients apply topical Eflornithine hydrochloride ointment as in arm I twice daily and topical Diclofenac sodium gel as in arm II once daily on days 1-90.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Histologic Score Diagnosis and Treatment Group</title>
          <description>Change scores were computed by subtracting baseline histologic score from End of Study histologic score. Slides were formalin fixed. Histologic Score has been developed by this research group over the course of Grant (reference below). A standardized form captures data on the following criteria: basal or suprabasilar pleomorphism (atypia); inflammation; hyperkeratosis; parakeratosis. The atypia and inflammation were rated as: none (0), mild to moderate(1), and severe (2). The remaining criteria were rated as present (1) or absent (0). Histologic Scores were computed by adding together the codes for the histologic criteria. Higher scores reflected higher level of epidermal /dermal damage.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.33" spread="0.15"/>
                    <measurement group_id="O2" value="0.26" spread="0.13"/>
                    <measurement group_id="O3" value="0.64" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Three months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arm I</title>
          <description>Patients apply topical eflornithine hydrochloride ointment to their left forearm twice daily on days 1-90.</description>
        </group>
        <group group_id="E2">
          <title>Arm II</title>
          <description>Patients apply topical diclofenac sodium gel to their left forearm once daily on days 1-90.</description>
        </group>
        <group group_id="E3">
          <title>Arm III</title>
          <description>Patients apply topical eflornithine hydrochloride ointment as in arm I twice daily and topical diclofenac sodium gel as in arm II once daily on days 1-90.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Burning/Stinging</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Rash, Redness, Erythema</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Joanne Jeter, MD</name_or_title>
      <organization>University of Arizona/Arizona Cancer Center</organization>
      <phone>520.626.9295</phone>
      <email>jjeter@azcc.arizona.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

